All Videos

Aaron Sookhoo, PA-C, and Andrew Mastro, PA-C, outline their long-term vision for the National Dermatology Leadership Summit, promoting collaboration and advocacy.

Panelists discuss how long-term management of melasma and postinflammatory hyperpigmentation requires lifelong maintenance regimens including retinoids for all patients, consistent sunscreen use with reapplication, proper diagnosis through biopsy when treatments fail to respond, and recognition that patients may have multiple concurrent conditions requiring different treatment approaches.

Discover how the National Dermatology Leadership Summit will unite PAs and NPs to enhance collaboration, education, and advocacy in dermatology.

Panelists discuss how long-term use of JAK inhibitors provides durable, real-world efficacy and consistent disease control for patients with atopic dermatitis.

Lindsay Ackerman, MD, outlines how ruxolitinib topical has transformed the clinical approach to vitiligo.

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

Peter Lio, MD, believes that collaboration between science and industry is vital for translating research into meaningful patient benefits.

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Clinicians are now aiming for treatment targets such as NRS 0–1, IGA 0–1, and EASI 90 to define successful AD management.

At Fall Clinical 2025, Shawn Kwatra, MD, presented insights on managing various cases of chronic itch, as well as understanding the OX40 ligand pathway as the “prequel to inflammation.”

Discover essential dermatology insights from experts at the Fall Clinical Conference 2025, featuring innovative treatment tips and patient care strategies.

Emerging skin treatments present unique clinical challenges that must be anticipated by clinicians.

Recent FDA approvals for topical roflumilast and ruxolitinib down to age 2 mark major milestones in managing pediatric AD, according to Peter Lio, MD.

At Fall Clinical 2025, Harrison Nguyen, MD, MBA, MPH, outlined how gene expression profile testing complements traditional staging systems by helping clinicians better identify melanoma and cSCC patients at the highest risk for recurrence.

Del Rosso recounts the meeting’s evolution and its consistent mission to bridge science and practice.

The AHEAD guidelines promote a new treatment standard for atopic dermatitis, emphasizing near-complete skin clearance and itch relief.

Panelists discuss how they incorporate both steroids and nonsteroidals from the initial visit by limiting steroid use to 1 to 2 weeks followed by long-term nonsteroidal maintenance, while noting the need for more vehicle formulations and lower age indications to better serve younger patients with limited treatment options.

Panelists discuss how extensive body surface area involvement in pediatric patients affects topical prescribing decisions, with high coverage areas often requiring systemic therapy consideration. They also discuss how location-specific factors like sensitive areas (face, groin) influence the choice toward nonsteroidal agents over topical steroids.

A new IPC-endorsed framework simplifies psoriasis severity into “topical” versus “systemic” categories to guide treatment more effectively, according to James Song, MD.

Peter Lio, MD, describes Fall Clinical as an energizing, high-level dermatology meeting focused on practical takeaways and collaboration.

Biologics, JAK inhibitors, and evolving treatment paradigms headline the Fall Clinical 2025 agenda.

Discover non-clinical career paths for PAs and NPs at the 2025 PDPA Keystone Conference, featuring insights from Shanna Miranti, MPAS, PA-C, and Lauren Miller, PA-C.

Cemiplimab is revolutionizing treatment for high-risk cutaneous squamous cell carcinoma, bridging gaps in care and improving patient outcomes.

Panelists discuss how postinflammatory hyperpigmentation (PIH) from acne requires simultaneous treatment of both the underlying acne and the resulting pigmentation using retinoids as first-line therapy, salicylic acid for exfoliation, and newer cosmeceuticals that can be tolerated even during isotretinoin therapy, emphasizing that treating pigmentation alone without addressing active acne is ineffective.

Panelists discuss how chemical peel selection must consider Fitzpatrick skin type with superficial peels safe for all patients while medium-depth peels require careful application in darker skin, and how treatment adherence is affected by multiple factors including application frequency, cost burden, insurance coverage limitations, and the need to manage patient expectations while accounting for concurrent use of social media–influenced products.

Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.

Vishal A. Patel, MD, discusses cemiplimab's FDA approval as a groundbreaking adjuvant therapy for high-risk cutaneous squamous cell carcinoma patients.

A panelist discusses how evolving trial standards and long-term safety considerations are redefining efficacy benchmarks and the role of oral systemics in psoriasis management.

The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.